FDA Places Bright Minds Biosciences Seizure Drug Application on Partial Hold
Bright Minds Biosciences said the FDA placed its drug application and planned trial for a seizure treatment on partial clinical hold following a review. The stock fell 36% to $35 in premarket trading Monday.
Kelly CloonanBright Minds Biosciences said the U.S. Food and Drug Administration put the company's application and planned trial for a drug to treat seizures on a partial clinical hold following a review.The stock slid 36% to $35 in premarket trading on Monday. Shares were down 30% year to date at…